Back to search
FDAFDA · Food and drugs·Recall number D-1056-2020

Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.05mg/0.03 mg, 0.075mg/0.04mg, and 0.125mg/0.03mg, packaged in 1 Wallet of 28 Tablets (NDC 68180-857-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-857-13); Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA.

Published March 18, 2020 · Recall initiated: March 9, 2020

Summary

FDA records drug Class II recall D-1056-2020, published March 18, 2020 and initiated March 9, 2020. Recalling firm: Lupin Pharmaceuticals Inc.; Status: Terminated; Reported quantity: 9,897 cartons; Lot: Lot #: L800951, Exp July 2020. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Content Uniformity Specifications: Out Of Specification test results observed for content uniformity.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Lupin Pharmaceuticals Inc.
Distributor
Nationwide in the USA and Puerto Rico.
Lot
Lot #: L800951, Exp July 2020
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Levonorgestrel and Ethinyl Estradiol Tablets USP, 0.05mg/0.03 mg, 0.075mg/0.04mg, and 0.125mg/0.03mg, packaged in 1 Wallet of 28 Tablets (NDC 68180-857-11), 3 Wallets of 28 Tablets Each per carton (NDC 68180-857-13); Rx Only, Distributed by: Lupin Pharmaceuticals, Inc., Baltimore, MD 21202; Manufactured by: Lupin Limited, Pithampur (M.P.) - 454775, INDIA. recalled?

Yes. FDA published recall D-1056-2020 on March 18, 2020. Reported hazard: Failed Content Uniformity Specifications: Out Of Specification test results observed for content uniformity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter